See the raw experimental evidence behind an author's publications and reproducibility signals.
Press Enter ↵ to solve
Fuel Your Discoveries
"The most incomprehensible thing about the world is that it is comprehensible."
- Albert Einstein
Quick Explanation
Copied
Seon Min Kim — scientific strength review
Based on the papers you provided (3 works listed), the author’s profile appears to center on diabetes-related digital/behavioral research plus at least one broader biomedical/translational theme; however, the current dataset is too small and potentially name-ambiguous to reliably infer an individual “Seon Min Kim” track record. Use the linked papers below to audit study design rigor, reproducibility practices, and biological/clinical relevance before concluding overall expertise.
No bioinformatics command was issued—this is a scientific critique of author evidence.
Long Explanation
Author Review: Seon Min Kim
Evidence used (from your provided dataset): You supplied 3 paper entries by “S. Kim” and also supplied rich per-paper technical summaries/quality scores for several additional DOIs. This response only critiques science that is explicitly present in that provided material.
Critical limitation: “Seon Min Kim” is a common name; the OpenAlex matching you included shows multiple similar author identities (e.g., different Kim variants). Without a unique identifier (ORCID) tying the listed works to one person, any “career trajectory” inference is name-disambiguation dependent (a major source of scientific error).
1) What the author’s provided body of work appears to be about
Diabetes & online communities / caregiver topics (your listed “paper count: 3” titles are diabetes-focused and qualitative/digital-social in framing).
Mechanistic biomedical cancer/immune/inflammation themes (your provided DOI set includes mechanistic preclinical oncology and immunology/inflammation style papers such as ferroptosis targeting in LUAD and mast-cell activation modulation).
Clinical prediction / imaging ML (radiomics-based risk prediction after pancreaticoduodenectomy for new-onset diabetes mellitus).
Epistemic skepticism note: Because the dataset mixes (a) your “author paper list” and (b) a separate “research data to utilize + graph” DOI bundle, it’s unclear if all mechanistic/ML papers belong to Seon Min Kim. Any inference about the author’s mechanistic expertise therefore has uncertainty tied to authorship attribution.
2) Evidence quality signals from your provided per-paper scores
You provided “paper_scientific_quality_score / novelty / reproducibility / usefulness / explanatory depth” for several DOIs. The bar chart below visualizes only those explicit scores.
Critical interpretation: These “scores” were supplied by you; they are not an external validated metric. I treat them as hypothesis-level annotations to structure critique, not as ground truth.
3) Study-design rigor audit (by example papers you provided with DOIs)
Because you did not provide full texts, I can only critique against the explicit methods/results/limitations you supplied. Still, that’s enough to identify recurring rigor themes: model choice, sample size, off-target risks, confounding, and translational limits.
3.1 Ferroptosis suppression dependency in KRAS-driven LUAD (FSP1/GPX4 axis)
The paper (your summary) uses in vivo GEMMs and orthotopic/xenograft models, CRISPR-based gene perturbations (Gpx4/Fsp1/Acsl4), and pharmacologic interventions including icFSP1, with lipidomics (LC-MS/epilipidomics) to connect mechanism to phenotypes. It also reports data availability via MassIVE for raw lipidomics.
Rigor strengths (from your provided content): multi-model convergence (GEMM + cell line rescue + PDX), mechanistic assays, and raw data deposition.
Rigor vulnerabilities / uncertainties: translational generalization still needs broader validation; long-term toxicity/safety remains unknown per your excerpt; CRISPR off-target effects are a generic concern; immune microenvironment effects are described as modestly explored.
3.2 Overcoming EGFR-TKI resistance via dual MET/AXL inhibition (NPS-1034)
Your summary indicates kinase profiling (DiscoveRx/Carna), generation/validation of resistant NSCLC cell line derivatives, combination-index analysis (CalcuSyn), Western blots and knockdown (siRNA) to implicate MET/AXL, and xenograft efficacy in SCID mice with tumor growth measures and histology markers.
Rigor strengths: mechanistic alignment (signaling + knockdown + combinations), and use of resistant subtypes.
Key vulnerabilities: multi-kinase off-targets weaken causal attribution to MET/AXL alone; small n in vivo and limited pharmacokinetic/toxicologic reporting.
Your excerpt indicates IgE receptor-mediated and calcium-dependent mast cell activation assays (β-hexosaminidase release; ionomycin/thapsigargin degranulation), cytokine expression (qRT-PCR + ELISA), and proximal signaling phosphorylation (Lyn/Syk/LAT/PLCγ1 and downstream MAPKs/NF-κB), with in vivo PCA vascular leakage endpoints.
Rigor strengths: mechanistic signaling mapping and two stimulus classes (IgE-mediated vs calcium-dependent).
Rigor weaknesses/uncertainties: no human validation; possible species translation gap; limited PK/toxicology; single acute hypersensitivity model.
3.4 Radiomics + clinical ML to predict long-term new-onset diabetes after pancreaticoduodenectomy
Your excerpt indicates a retrospective single-center cohort (n=126) with 47 cases and radiomic features extracted from preoperative and 3–6 month postoperative CT, plus 10 clinical variables; it reports feature selection (RFE), cross-validation, multiple ML classifiers, and SHAP interpretability.
Rigor strengths: explicit CV, comparison among models, and interpretability attempts (SHAP).
Key vulnerabilities: retrospective single-center datasets often overfit; external validation is required; imaging/radiomics reproducibility across scanners/protocols is a known Achilles heel, and cohort-specific confounding (e.g., chemotherapy regimen heterogeneity) can inflate apparent predictive value.
3.5 Ivermectin regimen for Aspiculuris tetraptera eradication in immunodeficient mouse colonies
Your excerpt reports multiple immunodeficient genotypes across 82 cages (Rag1-/-, Rag2-/-, C1qa-/-, TLR4-/-, TLR9-/-, TNF-α-/-, IL-10-/-, IL2RG-/- combinations) using fecal flotation and necropsy endpoints, with ivermectin injections plus environmental decontamination; it claims persistent eradication across 50 weeks and no mortality.
Rigor strengths: broad immunodeficient genotypic coverage and long post-cessation monitoring.
Rigor weaknesses: case-report style evidentiary strength is limited; environmental/colony management confounding is hard to fully rule out without controls.
3.6 Perfusion index as a nociception/pain marker during monitored anesthesia care
Your excerpt reports a prospective randomized comparison of propofol combined with remifentanil vs propofol combined with dexmedetomidine in adult patients undergoing chemoport insertion, measuring perfusion index (PI) and pain scores (NRS), along with rescue analgesia.
Rigor strengths: randomized clinical design.
Rigor weakness: weak correlation suggests biomarker non-specificity; generalization beyond this procedural context is uncertain.
Data-quality note: One DOI citation above is likely mismatched: the perfusion-index paper DOI in your dataset is 10.4062/biomolther.2025.164 for pluviatolide, while the perfusion-index paper DOI is 10.4062/biomolther.2025.164 in your list and 10.1186/s12871-023-02116-x is the one shown inside the “research data” bundle. In this response, I have only relied on the content strings you provided, but the DOI-to-title mapping needs correction for fully reliable bibliographic referencing.
4) Overall scientific strength—what can be concluded vs what cannot
What you can reasonably conclude from the provided evidence:
The provided set of papers includes mechanistic in vivo cancer/ferroptosis work, immunology signaling work, and a clinically oriented ML/radiomics prediction study.
Across these examples, there is recurring alignment between claimed mechanism and assays (signaling readouts, histology endpoints, lipidomics, or imaging-feature predictability).
What you cannot conclude confidently:
That “Seon Min Kim” personally produced all mechanistic/ML work in the DOI bundle, because the provided author list and the DOI bundle may refer to different individuals with similar names.
Long-term lab reproducibility practices (blinding protocols, preregistration, raw analysis code release) because the excerpts provide limited details on these items.
Disconfirming observations to look for:
Replication failures or inconsistent effect sizes across independent cohorts/models.
Evidence of reliance on correlative signals without causal follow-up (especially relevant for PI biomarkers and radiomics).
Authorship misattribution caused by name ambiguity (the biggest error risk here).
5) Visual summary of explicit “provided” score dimensions
The plot below uses only the per-paper “scientific quality” and “reproducibility” scores you provided (not external metrics).
Actionability
If you want this review to be a true author-grade assessment (not just “paper-grade critique”), provide:
an ORCID for the exact “Seon Min Kim” you mean, or
full citation list for the author (title + year), or
PDFs/links to the author’s publications.
That would resolve name ambiguity and enable a defensible mapping of skills/rigor to a single individual.
Feedback:
Updated: March 26, 2026
BGPT Author Review
Scientific Quality
40%
Moderate-to-low confidence because the provided information is incomplete and name-disambiguation is a major risk (multiple “Kim” identities appear). The included work spans mechanistic in vivo, immunology signaling, and clinical radiomics—suggesting competence across domains—but we cannot attribute those papers reliably to one individual, so overall scientific strength is underdetermined.
Communication Quality
50%
Only indirect communication evidence is present (your summaries). The summaries include methods and limitations fairly explicitly, but there’s not enough to judge clarity, framing, or precision of the author’s own writing.
Author Novelty
40%
Some included examples involve targeted mechanistic questions (e.g., ferroptosis dependency) and ML integration, but without a verified, complete author bibliography, novelty per-author cannot be credibly assessed.
Scientific Rigor
50%
Several provided examples show common rigor markers (in vivo models, mechanistic assay alignment, some data availability statements, explicit ML CV/feature selection). However, limitations such as small n in vivo, retrospective single-center design for ML, and translation uncertainty reduce determinacy; also authorship attribution ambiguity limits rigor evaluation per individual.
It will extract the provided per-paper score fields into a structured table, compute normalized comparisons across quality/reproducibility dimensions, and render updated Plotly charts for author-grade evidence mapping.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A “single biomarker” like perfusion index can robustly and specifically track nociception across procedures; this is unlikely given the explicitly reported weak correlation in the provided clinical study.
A dual-target inhibitor’s observed synergy with EGFR-TKIs is purely due to MET/AXL on-target effects with negligible contribution from off-target kinase suppression; this is at risk because multi-kinase activity is explicitly reported.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
